Studies on SLE treatment highlight that the synergistic effects of BLyS and APRIL are vital for maintaining the survival of autoreactive B cells and long-lived plasma cells, which persistently secrete autoantibodies, forming immune complexes that drive tissue inflammation and organ damage. This evidence concerns the gene TNFSF13 and systemic lupus erythematosus.